CompletedNCT01614912
This study exists to understand whether the medication SM-13496 is both safe enough and useful enough to take further. For people living with Schizophrenia, that matters because care needs to work in daily life, not just in theory.
SchizophreniaOtherFrom 18 Years to 74 Years
- Countries
- Japan, Malaysia, South Korea, Taiwan
- Sponsor
- Sumitomo Pharma Co., Ltd.
- Condition
- Schizophrenia
CompletedNCT02335658
This study exists to better understand the safety of the medication DSP-5423P and how manageable it feels in practice. For people living with Schizophrenia, that matters because care needs to work in daily life, not just in theory.
SchizophreniaOtherOver 18 Years
- Countries
- Japan
- Sponsor
- Sumitomo Pharma Co., Ltd.
- Condition
- Schizophrenia
CompletedNCT01614899
This study exists to compare options and see whether the medication SM-13496 offers something meaningfully different. For people living with Schizophrenia, that matters because care needs to work in daily life, not just in theory.
SchizophreniaOtherFrom 18 Years to 74 Years
- Countries
- Japan, Malaysia, South Korea, Taiwan
- Sponsor
- Sumitomo Pharma Co., Ltd.
- Condition
- Schizophrenia
CompletedNCT04325737
This study exists to compare options and see whether a medication treatment offers something meaningfully different. Researchers are trying to understand how people respond to a medication treatment in practice and what may need to be adjusted.
SchizophreniaOtherFrom 18 Years to 65 Years
- Countries
- Japan
- Sponsor
- Sumitomo Pharma Co., Ltd.
- Condition
- Schizophrenia
CompletedNCT02287584
This study exists to compare options and see whether the medication DSP-5423P offers something meaningfully different. For people living with Schizophrenia, that matters because care needs to work in daily life, not just in theory.
SchizophreniaOtherOver 18 Years
- Countries
- China, Japan, Malaysia, Philippines, Russian Federation, South Korea, Taiwan, Ukraine
- Sponsor
- Sumitomo Pharma Co., Ltd.
- Condition
- Schizophrenia
CompletedNCT00711269
This study exists to compare options and see whether the medication SM-13496 offers something meaningfully different. For people living with Schizophrenia, that matters because care needs to work in daily life, not just in theory.
SchizophreniaOtherFrom 18 Years to 74 Years
- Countries
- Japan, South Korea, Taiwan
- Sponsor
- Sumitomo Pharma Co., Ltd.
- Condition
- Schizophrenia
CompletedNCT03370640
This study exists to better understand the safety of a medication treatment and how manageable it feels in practice. Researchers are trying to understand whether a medication treatment can give earlier or clearer feedback during care.
SchizophreniaOtherFrom 18 Years to 55 Years
- Countries
- Japan
- Sponsor
- Sumitomo Pharma Co., Ltd.
- Condition
- Schizophrenia
TerminatedNCT03593213
This study exists to compare options and see whether a medication treatment offers something meaningfully different. Researchers are trying to understand whether a medication treatment can better prevent setbacks and support longer-term stability.
SchizophreniaOtherFrom 18 Years to 64 Years
- Countries
- Bulgaria, Malaysia, Poland, United States, Romania, Serbia, South Korea, Taiwan, Thailand, Ukraine
- Sponsor
- AbbVie
- Condition
- Schizophrenia
CompletedNCT01451736
This study exists to compare options and see whether a guided support group offers something meaningfully different. Researchers are trying to understand whether a guided support group can improve attention, thinking, or day-to-day functioning.
SchizophreniaOtherFrom 18 Years to 45 Years
- Countries
- United States
- Sponsor
- University of California, Los Angeles
- Condition
- Schizophrenia
CompletedNCT03554655
This study exists to see whether a digital app or remote support tool can play a useful role in care. Researchers are trying to understand whether a digital app or remote support tool can make support easier to access outside standard clinic visits.
SchizophreniaOtherFrom 18 Years to 35 Years
- Countries
- Denmark
- Sponsor
- Mental Health Centre Copenhagen, Bispebjerg and Frederiksberg Hospital
- Condition
- Schizophrenia
CompletedNCT04310475
This study exists to explore whether cognitive behavioural therapy, a structured talking treatment, could improve care and understanding. Researchers are trying to understand whether cognitive behavioural therapy, a structured talking treatment, can give earlier or clearer feedback during care.
SchizophreniaOtherFrom 18 Years to 65 Years
- Countries
- United Kingdom
- Sponsor
- King's College London
- Condition
- Schizophrenia
TerminatedNCT03852706
This study exists to see whether cognitive behavioural therapy, a structured talking treatment, is workable and worth testing more broadly. Researchers are trying to understand whether cognitive behavioural therapy, a structured talking treatment, can improve attention, thinking, or day-to-day functioning.
SchizophreniaOtherOver 18 Years
- Countries
- Ireland
- Sponsor
- University of Dublin, Trinity College
- Condition
- Schizophrenia
WithdrawnNCT04248010
This study exists to compare options and see whether the medication Individualized offers something meaningfully different. Researchers are trying to understand what the medication Individualized can reveal about signals in the brain or body that may guide care later on.
SchizophreniaOtherFrom 18 Years to 55 Years
- Countries
- Global
- Sponsor
- Columbia University
- Condition
- Schizophrenia
Not Yet RecruitingNCT04798131
This study exists to see whether a digital app or remote support tool can play a useful role in care. Researchers are trying to understand what a digital app or remote support tool can reveal about signals in the brain or body that may guide care later on.
SchizophreniaOtherFrom 18 Years to 60 Years
- Countries
- Global
- Sponsor
- University Hospital, Lille
- Condition
- Schizophrenia
CompletedNCT03870880
This study exists to understand how a digital app or remote support tool holds up over time after the earliest research stage. Researchers are trying to understand whether a digital app or remote support tool can give earlier or clearer feedback during care.
SchizophreniaOtherFrom 18 Years to 65 Years
- Countries
- Ukraine, United States
- Sponsor
- Rovi Pharmaceuticals Laboratories
- Condition
- Schizophrenia
TerminatedNCT03261817
This study exists to see whether this type of care can play a useful role in care. Researchers are trying to understand whether this type of care can improve attention, thinking, or day-to-day functioning.
SchizophreniaOtherFrom 18 Years to 60 Years
- Countries
- France
- Sponsor
- University Hospital, Caen
- Condition
- Schizophrenia
CompletedNCT00554840
This study exists to see whether smoking support or smoking-related treatment is workable and worth testing more broadly. Researchers are trying to understand whether smoking support or smoking-related treatment can improve attention, thinking, or day-to-day functioning.
SchizophreniaOtherFrom 18 Years to 64 Years
- Countries
- Global
- Sponsor
- University of Maryland, Baltimore
- Condition
- Schizophrenia
CompletedNCT00161044
This study exists to explore whether a therapy or guided support program could improve care and understanding. Researchers are trying to understand whether a therapy or guided support program can improve attention, thinking, or day-to-day functioning.
SchizophreniaOtherFrom 18 Years to 60 Years
- Countries
- United States
- Sponsor
- University of Maryland, Baltimore
- Condition
- Schizophrenia
WithdrawnNCT01584466
This study exists to understand what helps a medication treatment work in everyday practice, not just under ideal conditions. Researchers are trying to understand whether a medication treatment can work better when mental health difficulties overlap with substance use.
SchizophreniaOtherFrom 18 Years to 64 Years
- Countries
- United States
- Sponsor
- University of Maryland, Baltimore
- Condition
- Schizophrenia
CompletedNCT00176436
This study exists to explore whether a guided support group could improve care and understanding. Researchers are trying to understand what a guided support group could change in day-to-day care and decision-making.
SchizophreniaOtherFrom 18 Years to 65 Years
- Countries
- United States
- Sponsor
- University of Maryland, Baltimore
- Condition
- Schizophrenia
CompletedNCT01182727
This study exists to see whether a digital app or remote support tool is workable and worth testing more broadly. Researchers are trying to understand how people respond to a digital app or remote support tool in practice and what may need to be adjusted.
SchizophreniaOtherFrom 18 Years to 65 Years
- Countries
- United States
- Sponsor
- University of Maryland, Baltimore
- Condition
- Schizophrenia
CompletedNCT04783285
This study exists to understand how a digital app or remote support tool holds up over time after the earliest research stage. Researchers are trying to understand whether a digital app or remote support tool can improve attention, thinking, or day-to-day functioning.
SchizophreniaOtherFrom 18 Years to 64 Years
- Countries
- Portugal
- Sponsor
- CEDIARA - Assoc. Solidariedade Social de Ribeira de Fráguas
- Condition
- Schizophrenia
CompletedNCT00708994
This study exists to explore whether brain scans or other body measurements could improve care and understanding. Researchers are trying to understand what brain scans or other body measurements can reveal about signals in the brain or body that may guide care later on.
SchizophreniaOtherFrom 18 Years to 55 Years
- Countries
- United States
- Sponsor
- Yale University
- Condition
- Schizophrenia
CompletedNCT03466112
This study exists to explore whether this type of care could improve care and understanding. Researchers are trying to understand whether this type of care can improve attention, thinking, or day-to-day functioning.
SchizophreniaOtherFrom 18 Years to 65 Years
- Countries
- Germany
- Sponsor
- Ludwig-Maximilians - University of Munich
- Condition
- Schizophrenia
CompletedNCT01514682
This study exists to see whether a therapy or guided support program can play a useful role in care. Researchers are trying to understand whether a therapy or guided support program can improve attention, thinking, or day-to-day functioning.
SchizophreniaOtherFrom 18 Years to 60 Years
- Countries
- United States
- Sponsor
- University of Maryland, Baltimore
- Condition
- Schizophrenia